Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

GU medical oncologist Dr. Rana McKay and urologist Dr. Neal Shore explore how predictive biomarkers and genetic testing are informing risk assessment and guiding personalized treatment decisions in clinical practice.

EP: 1.Metastatic Prostate Cancer: Background and Patient Prognosis

Now Viewing

EP: 2.Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

EP: 3.Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life

EP: 4.Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis

EP: 5.Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer

EP: 6.Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape

EP: 7.Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer

Related Videos

Related Content

Advertisement

July 15th 2025

CMS issues reimbursement code for PSMA-PET imaging agent Gozellix

Hannah Clarke

The level II code A9616 will be effective starting on October 1, 2025.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 14th 2025

Study shows favorable outcomes with guideline-based treatment for localized prostate cancer

Hannah Clarke

“Our data support adherence to guideline recommendations for treatment of prostate cancer,” says Pietro Scilipoti, MD.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 10th 2025

EMBARK: Significant OS gains seen with enzalutamide plus leuprolide in nmHSPC

Benjamin P. Saylor

According to the news release, detailed OS data from EMBARK are set to be presented at an upcoming medical conference.

July 9th 2025

FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

Benjamin P. Saylor Hannah Clarke

The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.

Related Content

Advertisement

July 15th 2025

CMS issues reimbursement code for PSMA-PET imaging agent Gozellix

Hannah Clarke

The level II code A9616 will be effective starting on October 1, 2025.

July 15th 2025

Pearls & Perspectives: Testosterone and the Future of Men’s Health, with John P. Mulhall, MD

Amy M. Pearlman, MD

Mulhall offers an unfiltered, evidence-based deep dive into testosterone evaluation and treatment nuances.

July 14th 2025

Study shows favorable outcomes with guideline-based treatment for localized prostate cancer

Hannah Clarke

“Our data support adherence to guideline recommendations for treatment of prostate cancer,” says Pietro Scilipoti, MD.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 10th 2025

EMBARK: Significant OS gains seen with enzalutamide plus leuprolide in nmHSPC

Benjamin P. Saylor

According to the news release, detailed OS data from EMBARK are set to be presented at an upcoming medical conference.

July 9th 2025

FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

Benjamin P. Saylor Hannah Clarke

The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.